Here’s What Eli Lilly’s Latest Clinical Win Means For Investors
Few pharmaceutical giants have performed as well or better than Eli Lilly (NYSE: LLY) in the stock market over the past year. Moreover, the drug manufacturer's shares outperformed the broader market and the Health Care Select Sector SPDR Fund by wide margins.
The Indianapolis-based company's secret wasn't its financial results, as they were relatively mild, or even downright disappointing, for much of this period. So what's been driving Eli Lilly's stock? The company's promising drug pipeline.
The market is forward-looking, and with the drugmaker producing several highly promising programs, investors are increasingly excited regarding Eli Lilly's future. And recently, the company reported another important clinical win that could lead to a major approval. Let's look at this latest development and discuss what it means for Eli Lilly and its shareholders.
Source Fool.com
